These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 12771643)

  • 21. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B; Pawlak K; Myśliwiec M
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of thromboelastography to demonstrate persistent anticoagulation after stopping enoxaparin.
    Simons R; Mallett SV
    Anaesthesia; 2007 Nov; 62(11):1175-8. PubMed ID: 17924901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Summary and perspectives. Rivaroxaban].
    Albaladejo P
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Routine laboratory monitoring for low-molecular-weight heparin prophylaxis in burns? Not so fast!
    Lundy JB; Lairet K; Chung KK; Renz EM
    J Burn Care Res; 2011; 32(4):e155. PubMed ID: 21577136
    [No Abstract]   [Full Text] [Related]  

  • 26. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once atrial fibrillation, always oral anticoagulation?
    Verheugt FW
    Thromb Res; 2007; 119(3):275-6. PubMed ID: 16426666
    [No Abstract]   [Full Text] [Related]  

  • 28. Enoxaparin as prophylaxis against thromboembolism after total hip replacement.
    Anderson DR; Gross M; Robinson KS; Wells PS
    N Engl J Med; 1997 Feb; 336(8):585; author reply 586. PubMed ID: 9036310
    [No Abstract]   [Full Text] [Related]  

  • 29. Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1116-24; discussion 1125-6. PubMed ID: 12813332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
    Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
    J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic analysis of enoxaparin in a term neonate and review of literature.
    Mateos MK; Wright FA; Cohn RJ
    Thromb Res; 2013 Oct; 132(4):487-9. PubMed ID: 23992876
    [No Abstract]   [Full Text] [Related]  

  • 32. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.
    Marlovits S; Striessnig G; Schuster R; Stocker R; Luxl M; Trattnig S; Vécsei V
    Arthroscopy; 2007 Jul; 23(7):696-702. PubMed ID: 17637403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rivaroxaban (Xarelto): efficacy and safety].
    Rosencher N; Arnaout L; Chabbouh T; Bellamy L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S22-7. PubMed ID: 19185784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term oral coagulation. Self monitoring prevents complication].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813982
    [No Abstract]   [Full Text] [Related]  

  • 37. Enoxaparin in acute coronary syndromes.
    Lee S; Gibson CM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
    Tebbe U
    Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
    Tran H; McRae S; Ginsberg J
    Cardiol Clin; 2008 May; 26(2):235-50, vi-vii. PubMed ID: 18406997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjusting the dose of low molecular weight heparins in renally impaired and obese patients.
    Spinler S
    Clin Adv Hematol Oncol; 2004 May; 2(5):270, 273-4. PubMed ID: 16163192
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.